Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal BCMA and CD19 CAR-T in Refractory Lupus Nephritis
NCT06681337Phase 1Not yet recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of BCMA-UCART and universal CD19 CAR-T in lupus nephritis (LN), sponsored by BRL Medicine Inc. Primary endpoint: Adverse Events at 6 months. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
BCMA-UCARTuniversal CD19 CAR-T
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06681337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681337.